The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
AstraZeneca Pharma India discontinues manufacturing of Imdur
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
The company will now explore a buyer for its manufacturing site and exit in due course
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Subscribe To Our Newsletter & Stay Updated
